Gsk Plc ADR (GSK)
$39.08
0.32 (0.80%)
GSK Stock Quote Delayed 30 Minutes
Don’t Buy Pharma Stocks — Buy THESE Pharma Stocks
If your sliver of the pharma pie is too small, it's easy to fall into the "any old pharma stock will do" trap. Keep your eye on the prize with these must-own names.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
210.43B
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
129,427
Day's Range
$39.06 - $39.27
52-Week Range
$33.67 - $45.92
Dividend & Yield
$1.44 (3.70%)
GSK Stock Predictions, Articles, and Gsk Plc ADR News
Gilead Sciences’ HIV Drugs Clear a Hurdle
Full FDA approval should come next -- but if not, watch out, because Gilead is very heavily dependent on its HIV drug lineup, and patents will be expiring.
Should I Buy Colgate-Palmolive Stock? 3 Pros, 3 Cons
Colgate-Palmolive reached all-time highs above the $100 threshold on Tuesday. But after a steady run-up in 2012, is it still worth buying in now?
Obesity: The Next Investment Driver
The global market for weight-control products of all types is forecast to hit $53 billion in just five years, and several companies are primed to profit.
Top 10 New Products Flying Off Store Shelves
These items introduced in 2011 reeled in the leading sales, among them Pampers Cruiser/Swaddlers with Dry Max and Nicorette Lozenge.
A Good Day or a Bad Day — It All Depends
Human Genome Sciences and eBay were among the big winners in the market on Thursday on a takeover bid and good earnings. As for some others, not such a good day
Cue the Biotech M&A Attack!
A rush of buyout activity in biotechs like Human Genome and Illumina could produce more frenzied M&A deals down the road.
Ups and Downs the Norm — Thursday’s IP Market Recap
Markets went on a roller-coaster ride again today, starting with an early move up and coming down the remainder of the day on disappointing economic news.
Stock Pick of The Day: Dyax
Dyax is a maker of anti-inflammation drugs, an area with a growing base of patients. While in the early stages of growth, the company shows great promise.
CNNMoney: 10 Fastest Growing Cities in America
What they have that new residents are seeking: Mild weather, good job prospects and low costs.
5 Global Stock Buys and 2 Sells
There a number of outstanding opportunities in European stocks, as long as you can do the work to find them. Here are 5 top performers to start with now.
Picking Winners in Energy, Oil, and Financials
Recent economic data, European activities, and oil price changes have led to strong buying opportunities for savvy investors
Here Comes a Bidding War for Amylin
Approval of its diabetes drug has Big Pharma banging on its door, with Bristol-Myers Squibb already said to have offered $3.5 billion, or $22 per share.
Generic Versions of Boniva Approved By the FDA
The FDA approved the first generic versions of osteoporosis drug Boniva, allowing manufacturers like Apotex, Orchid Healthcare and Mylan to make the drug.
9 Pharma Buys for a Healthy Portfolio
Their dividends are attractive, and some drugmakers have made great progress in refilling their pipelines.
Breaking Down Societe Generale’s Top 40 Dividend Stocks in the World
Societe Generale recently put out its annual list of the top 40 dividend payers across the globe. Here's a look at those companies, as well as a few trends.
10 Pharma Blue Chips to Buy
There are a number of great companies in pharma if you know where to look.
10 Pharma Stocks to Add to Your Portfolio…Stat
Investors have plenty of reasons to invest in the health care industry. With returns like these, it's no wonder investors are scrambling to own them.
Amylin Gets a Boost From Its Diabetes Drug Approval
FDA approval of Bydureon -- a once-a-week injectable drug -- could make Amylin a takeover target for a Big Pharma.
Small Patient Population? Charge $400K a Year for Your Drug
Companies like BioMarin Pharmaceutical are cashing in on rare diseases, where they can charge hundreds of thousands of dollars every year for their drugs.
8 Pharma Stocks in Good Health
The health care sector is a field that will continue to grow as Baby Boomers get old and retire. These eight companies will be at the center of this trend.
